As TNBC showed higher levels of PD-L1 and IDO compared with other breast cancer subtypes, IDO inhibitors are being evaluated in combination with PD-1/PD-L1 inhibition in preclinical and clinical settings [207,232]. Here, IDO1 is linked to breast carcinoma.